Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

TGA Issues Guidance on Device Conformity Assessments During COVID-19

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

Australia’s Therapeutic Goods Administration (TGA) said that, in light of delays due to the COVID-19 pandemic and limitations on the number of notified bodies designated under the European Medical Devices…

Continue ReadingTGA Issues Guidance on Device Conformity Assessments During COVID-19

FDA Issues First Warning Letter for Product With a COVID-19-Related EUA

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

FDA hit Columbus, Ohio-based Battelle Memorial Institute with a warning letter for failure to comply with terms of its Emergency Use Authorization (EUA) for its decontamination system used for N95…

Continue ReadingFDA Issues First Warning Letter for Product With a COVID-19-Related EUA

Former FDA Official Advises on Best GMP practices During the Pandemic

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

Many of the guidance documents for drug developers and manufacturers that the FDA has issued during the COVID-19 pandemic are likely to continue to be in effect long after the…

Continue ReadingFormer FDA Official Advises on Best GMP practices During the Pandemic

483 Roundup: Five Drugmakers Cited for Quality Failures

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

FDA investigators cited five drug facilities for failures ranging from late field reports to lax control of data, complaint handling and training. Source: Drug GMP Report

Continue Reading483 Roundup: Five Drugmakers Cited for Quality Failures

New Postmarket Reporting Forms Detailed in Draft Guidance

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

The FDA has developed two new documents that it wants drug sponsors to use for annual postmarket reporting and is requesting comments on them in a new draft guidance. Source:…

Continue ReadingNew Postmarket Reporting Forms Detailed in Draft Guidance

Warning Letter Roundup: FDA Raps Three Firms for GMP, Other Lapses

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

The FDA issued warning letters to three drug manufacturing facilities for failures in their current good manufacturing practices, including lax environmental monitoring and inadequate process validations. Source: Drug GMP Report

Continue ReadingWarning Letter Roundup: FDA Raps Three Firms for GMP, Other Lapses

Dr. Reddy’s Temporarily Shutters Data Centers Following Cyber Attack

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical companies, announced Thursday that it has temporarily shut down all of its data center services in response to a cyberattack. Source: Drug…

Continue ReadingDr. Reddy’s Temporarily Shutters Data Centers Following Cyber Attack

GAO Tells FDA It Has Work to Do on Its Office of Laboratory Safety

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

The Government Accountability Office (GAO) wants the FDA to institute several changes to its three-year-old Office of Laboratory Safety (OLS), which was formed to improve safety in the agency’s labs…

Continue ReadingGAO Tells FDA It Has Work to Do on Its Office of Laboratory Safety

COVID-19 Vaccine Developers Don’t Need Pre-Approval Inspections for Emergency Use

  • Post author:Sam
  • Post published:November 5, 2020
  • Post category:Drug GMP Report

The FDA will not make COVID-19 vaccine developers go through pre-approval inspections for an Emergency Use Authorization (EUA), but companies will have to submit detailed manufacturing data and meet certain…

Continue ReadingCOVID-19 Vaccine Developers Don’t Need Pre-Approval Inspections for Emergency Use

Agios Withdraws European Tibsovo AML Submission

  • Post author:Sam
  • Post published:October 20, 2020
  • Post category:Drug Industry Daily

Agios has withdrawn its EU marketing authorization application to the European Medicines Agency for Tibsovo (ivosidenib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) featuring…

Continue ReadingAgios Withdraws European Tibsovo AML Submission
  • Go to the previous page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.